Athera Biotechnologies AB

March 02, 2012 08:08 ET

Annexin A5 at low doses prevents atherosclerosis - Study published in Atherosclerosis

SOLNA, SWEDEN--(Marketwire - Mar 2, 2012) - Treatment with low doses of recombinant Annexin A5 prevents vascular remodelling in a preclinical study. These results were recently published in an article in Atherosclerosis.

Patients who undergo common surgery for cardiovascular disease are at risk for inflammation-driven complications after the intervention. It has previously been shown that Annexin A5 beneficially affects remodelling in a preclinical model of coronary bypass grafting.

This study showed that Annexin A5 could prevent injury induced accelerated atherosclerosis and thickening of the vascular intima, in a model mimicking catheter-based percutaneous interventions (PCI) in mice. The results confirm that the anti-inflammatory effect of recombinant Annexin A5 could be seen in doses 3-10 times lower than previously investigated. PCI has become a gold standard in rapidly treating patients with acute heart attack. Millions of PCI procedures are done per year due to acute coronary syndrome (ACS) and the number is rapidly increasing.

"These recently published findings support our approach to develop recombinant Annexin A5 as an anti-inflammatory therapy, primarily targeting prevention of complications following vascular surgery. We have successfully developed a cost-effective manufacturing process which has been transferred to the cGMP facility and we are now actively discussing co-development opportunities for further preclinical and clinical studies", says Carina Schmidt, CEO of Athera.

About Athera Biotechnologies AB (publ) Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach.

Athera's vision is to develop recombinant Annexin A5 for prevention of complications in patients with peripheral artery disease (PAD) undergoing vascular surgery. The project is currently in preclinical phase.

PC-mAb from Athera is in late preclinical development, using a unique fully human monoclonal antibody. PC-mAb is being developed to restore cardio-protective levels of anti-PC and prevent secondary CVD events after acute coronary syndrome. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera's novel therapeutics.

Athera, a Swedish company, is part of the Karolinska Development AB (publ) portfolio.

News Release as PDF:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Athera Biotechnologies AB via Thomson Reuters ONE


Contact Information

  • For further Information:
    Athera Biotechnologies AB (publ)
    Chief Executive Officer
    Carina Schmidt
    Tel +46 761938190
    Email Contact